



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**Datasheet for 100-4165NP****NFKB p65 (Rel A) N-Terminal Specific Peptide****Overview**

<b>Description:</b>	NFKB p65 (Rel A) N-Terminal Specific Peptide - 100-4165NP
<b>Item No.:</b>	100-4165NP
<b>Size:</b>	50 µg
<b>Origin:</b>	Human

**Product Details**

**Background:** Intended for use as a control peptide when used with anti-NFKB p65 to block specific interaction of anti-NFKB p65 (p/n 100-4165) with the NFKB p65 RelA. NFKB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFKB bound to IκB. NFKB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFKB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IκB-α. IκB-α binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.

<b>Synonyms:</b>	NFKB p65 peptide, RelA peptide, Transcription factor p65, control peptide, blocking peptide
<b>Species of Origin:</b>	Human
<b>Type:</b>	Peptide

**Target Details**

**Purity/Specificity:** Greater than 95% specific peptide

**Application Details**

**Application Note:** Control peptide should be used at 1.0 µg per 1.0 µl of antiserum in per assay.

**Assay Dilutions:** All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

---

## Formulation

<b>Physical State:</b>	Liquid (sterile filtered)
<b>Concentration:</b>	1.0 mg/mL by dry weight
<b>Buffer:</b>	None
<b>Preservative:</b>	0.01% (w/v) Sodium Azide
<b>Stabilizer:</b>	None

---

## Shipping & Handling

<b>Shipping Condition:</b>	Dry Ice
<b>Storage Condition:</b>	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
<b>Expiration:</b>	Expiration date is six (6) months from date of receipt.

---

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

